Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 3Completed 3Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 2Hematologic Neoplasms 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Esophageal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Rituximab 15Cyclophosphamide 12fludarabine phosphate 11ibrutinib 10Bendamustine Hydrochloride 9fludarabine 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 6venetoclax 4Whole-Body Irradiation 4Radiotherapy 4idelalisib 3duvelisib 3acalabrutinib 3Mycophenolic Acid 3Methotrexate 3Melphalan 3In Situ Hybridization, Fluorescence 3Flow Cytometry 3Filgrastim 3Cytarabine 3Cyclosporine 3ofatumumab 2obinutuzumab 2Thiotepa 2Tacrolimus 2Pentetic Acid 2Etoposide 2Dexamethasone 2Dasatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Lymphocytic, Chronic, B-Cell × CTLA-4 Antigen × Clear all
NCT04781855 2025-02-28

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡